arrow
A

Abdüssamet Çelebi

department of medical oncology
H指数:6
被引数:144

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

基线和早期治疗中的预后营养指数在激素受体阳性、HER2阴性转移性乳腺癌患者中的应用(接受CDK4/6抑制剂治疗)

2026-09-020
OA
Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

晚期胸腺癌二线治疗的实际疗效:一项多中心土耳其肿瘤学组(TOG)研究

2026-08-270
OA
Long-Term Outcomes and Conditional Recurrence-Free Survival in Stage II Colon Cancer: The Impact of Surveillance and Recurrence Detection Strategies

II期结肠癌的长期结局与条件无复发生存率:监测和复发检测策略的影响

2026-06-240
OA
Prognostic Value of 18F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
2026-01-260
OAAI
Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group
2025-03-170
OAAI
Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization

预后营养指数作为转移性激素敏感型前列腺癌的生物标志物:对生存期和治疗优化的影响

2025-02-190
OAAI
Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors
2025-02-070
OAAI
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
2024-03-093
OAAI
The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study

低HER2表达对接受CDK4/6抑制剂联合内分泌治疗的转移性激素受体阳性乳腺癌患者治疗结局的影响: 一项多中心回顾性研究

BREAST
IF7.9
2023-08-019
OAAI
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)

在CDK 4/6抑制剂治疗下疾病进展的激素阳性晚期乳腺癌患者中后续治疗的疗效 (第23卷,136,2023)

2023-02-272
OAAI
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

在CDK 4/6抑制剂治疗下疾病进展的激素阳性晚期乳腺癌患者的后续治疗效果

2023-02-1016
OAAI
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
BREAST
IF7.9
2022-12-0112
OAAI